| scholarly article | Q13442814 |
| P50 | author | Han Yong Choi | Q85904531 |
| P2093 | author name string | Do-Hyun Nam | |
| Kyeung Min Joo | |||
| Hye Won Lee | |||
| Seong Soo Jeon | |||
| Byong Chang Jeong | |||
| Sharon Lim | |||
| Da Eun Jeong | |||
| Joung Eun Lim | |||
| Hye Jin Jin Song | |||
| Se Jeong Jeong Lee | |||
| P2860 | cites work | VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling | Q22009049 |
| Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action | Q22061792 | ||
| Current perspectives on the mechanism of action of artemisinins | Q22061943 | ||
| Suppression of cancer cell growth by promoting cyclin D1 degradation | Q24317660 | ||
| Apoptosis, oncosis, and necrosis. An overview of cell death | Q24684007 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| The calpain system | Q28185062 | ||
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 | ||
| The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer | Q28257323 | ||
| Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells | Q28306865 | ||
| Cyclin B1 and CDK1: nuclear localization and upstream regulators | Q28611376 | ||
| Iron, brain ageing and neurodegenerative disorders | Q29615656 | ||
| Tumorigenesis and the angiogenic switch | Q29619849 | ||
| Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines | Q30425118 | ||
| Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent | Q30834716 | ||
| Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis | Q33384203 | ||
| The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma | Q33566593 | ||
| Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo | Q33666019 | ||
| The influence of natural products upon drug discovery | Q33908826 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron | Q34344151 | ||
| Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1. | Q34382566 | ||
| From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs | Q34568416 | ||
| Morphological and biochemical aspects of apoptosis, oncosis and necrosis | Q34797912 | ||
| Metastatic renal cell carcinoma | Q35206797 | ||
| Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug | Q35585226 | ||
| The role of calpain in oncotic cell death | Q35639152 | ||
| Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease | Q35741510 | ||
| Vascular endothelial growth factor and angiogenesis | Q35985850 | ||
| Tumor angiogenesis and therapy | Q36409381 | ||
| Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity | Q36811863 | ||
| Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation | Q36973937 | ||
| Cancer cells survive with survivin | Q37185505 | ||
| Enhancing the cytotoxic activity of novel targeted therapies--is there a role for a combinatorial approach? | Q37239233 | ||
| Transcription-independent functions of MYC: regulation of translation and DNA replication | Q37242438 | ||
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. | Q37379113 | ||
| Novel therapeutic inhibitors of the c-Met signaling pathway in cancer | Q37422804 | ||
| Anticancer activities of artemisinin and its bioactive derivatives | Q37626137 | ||
| Effects of artesunate on cytokinesis and G₂/M cell cycle progression of tumour cells and budding yeast. | Q38338694 | ||
| Anticancer Effect of AntiMalarial Artemisinin Compounds | Q38414908 | ||
| The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer | Q38948059 | ||
| Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma | Q39101536 | ||
| Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma. | Q39104237 | ||
| Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo | Q39108206 | ||
| Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71. | Q39131904 | ||
| Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide | Q39263561 | ||
| A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma | Q39532016 | ||
| Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines | Q39809835 | ||
| Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate | Q39840163 | ||
| The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. | Q39886511 | ||
| High concentrations of ascorbic acid induces apoptosis of human gastric cancer cell by p38-MAP kinase-dependent up-regulation of transferrin receptor | Q39901668 | ||
| Artesunate derived from traditional Chinese medicine induces DNA damage and repair. | Q39976238 | ||
| Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species | Q39991619 | ||
| Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature | Q40270911 | ||
| Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. | Q40325894 | ||
| Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. | Q40567286 | ||
| Rapid responses to oxidative stress mediated by iron regulatory protein. | Q40807123 | ||
| Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis | Q41115305 | ||
| The pathways of cell death: oncosis, apoptosis, and necrosis | Q41376310 | ||
| Metastatic patterns of renal carcinoma: an analysis of 687 necropsies | Q41407886 | ||
| First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases | Q43128296 | ||
| Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma | Q43407740 | ||
| Ischemia leads to apoptosis--and necrosis-like neuron death in the ischemic rat hippocampus. | Q45191529 | ||
| Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression | Q45329566 | ||
| Dihydroartemisinin is an inhibitor of ovarian cancer cell growth | Q47776445 | ||
| Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. | Q53668779 | ||
| Renal-Cell Carcinoma | Q56019528 | ||
| Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells | Q74255134 | ||
| ATP-dependent steps in apoptotic signal transduction | Q77415615 | ||
| Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway | Q80372653 | ||
| Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells | Q80506793 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 32 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| artesunate | Q707939 | ||
| renal cell carcinoma | Q1164529 | ||
| metastatic renal cell carcinoma | Q19000948 | ||
| P304 | page(s) | 33046-33064 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis | |
| P478 | volume | 6 |
| Q38712611 | Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action. |
| Q92890347 | Artemisinin induced reversal of EMT affects the molecular biological activity of ovarian cancer SKOV3 cell lines |
| Q36057706 | Artesunate induces ROS-dependent apoptosis via a Bax-mediated intrinsic pathway in Huh-7 and Hep3B cells |
| Q64889684 | Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells, and autophagy inhibition enhances the artesunate‑induced apoptosis. |
| Q91272140 | Artesunate induces mitochondria-mediated apoptosis of human retinoblastoma cells by upregulating Kruppel-like factor 6 |
| Q47166468 | Artesunate inhibits proliferation and invasion of mouse hemangioendothelioma cells in vitro and of tumor growth in vivo |
| Q97652850 | Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma |
| Q92241233 | Cytotoxic Effects of Artemisia annua L. and Pure Artemisinin on the D-17 Canine Osteosarcoma Cell Line |
| Q36162825 | Downregulation of HOTAIR Expression Mediated Anti-Metastatic Effect of Artesunate on Cervical Cancer by Inhibiting COX-2 Expression |
| Q108003603 | Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma |
| Q36909297 | Iron and cancer: recent insights |
| Q38637192 | Iron, Oxidative Damage and Ferroptosis in Rhabdomyosarcoma |
| Q46250415 | More insights into the pharmacological effects of artemisinin |
| Q42207079 | Nanoparticle Delivery of Artesunate Enhances the Anti-tumor Efficiency by Activating Mitochondria-Mediated Cell Apoptosis |
| Q89989620 | New drugs are not enough‑drug repositioning in oncology: An update |
| Q58692208 | Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways |
| Q37543809 | Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis |
| Q36962480 | Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer |
| Q28821190 | Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation |
| Q37699414 | Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis |
| Q51147639 | Screening for biologically annotated drugs that trigger triacylglycerol accumulation in the diatom Phaeodactylum. |
| Q58221043 | The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma |
| Q36118474 | β2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase |
Search more.